Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
about
Advances in Precision Medicine: Tailoring Individualized Therapies.Epigenetic mechanisms in health and disease: BCEC 2017.Precision Medicine in Hormone Receptor-Positive Breast Cancer.Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling
P2860
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@en
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@nl
type
label
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@en
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@nl
prefLabel
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@en
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Acquired CYP19A1 amplification ...... ERα metastatic breast cancer.
@en
P2093
Giacomo Corleone
Giancarlo Pruneri
Gianmaria Frige
Iros Barozzi
Mannus H Kempe
Pernette J Vershure
Raffaella Maria Gadaleta
Saverio Minucci
Sonia Fabris
P2860
P2888
P304
P356
10.1038/NG.3773
P407
P577
2017-01-23T00:00:00Z